Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

October 31, 2026

Conditions

Coagulation Disorder

Interventions

DRUG

VMX-C001

VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs

DRUG

Rivaroxaban

FXa Inhibitor

DRUG

UFH

Unfractionated Heparin

DRUG

Enoxaparin

Low Molecular Weight Heparin

Trial Locations (1)

ICON, Groningen

All Listed Sponsors

lead

VarmX B.V.

INDUSTRY

NCT06517563 - Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin | Biotech Hunter | Biotech Hunter